Search Result

• All
• Related Products
• Other Content

• Industry Insight | Lentiviral Vectors Power Next Wave of In Vivo CAR-T Development March 2026 — Global Biotech NewsLentiviral vector technology continues to play a central role in the evolution of CAR-T cell therapies, as researchers advance strategies aimed at delivering chimeric ... More+
• Instructions for Use of CD-19 Lentivirus (VSV-G)
• Company Recognition | Upgrading Dimensions · Expanding Horizons · Shaping the Future | Hillgene 2026 Spring Gala Successfully Concluded As spring ushers in a new beginning, everything is renewed with vitality. On March 6, 2026, Hillgene successfully held its Spring Gala themed “Upgrading Capabilities · Expanding Horizons · Shaping ... More+
• Instructions for Use of CD-19 Lentivirus（Baev）
• Industry Insight | Iovance Reports New Clinical Data for TIL Therapy in Soft Tissue Sarcoma Iovance Biotherapeutics announced new clinical results for its tumor-infiltrating lymphocyte (TIL) therapy Lifileucel in patients with soft tissue sarcoma, highlighting the potential expansion of TIL ... More+
• Instructions for Use of HiPlas™ LentiHelper Plasmids for T
• Industry Insight | As iNKT Moves Forward, Cell Therapy Competition Shifts from Efficacy to Manufacturability The recent collaboration between MiNK Therapeutics and C-Further to advance a PRAME-targeted iNKT cell therapy for pediatric cancers reflects more than a single pipeline update. As noted in recent ind... More+
• Instructions for Use of Host Cell Protein Residual Detection Kit for Escherichia coli（2G)
• Industry Insight | From Process Optimization to AI-Driven Quality Control: NK Cell Therapy Enters a Manufacturing-Driven Phase Meribank Biotech has recently announced a new collaboration focused on upgrading manufacturing capabilities for NK cell therapies, including process optimization and the integration of AI-driven quali... More+
• Company Recognition | Hillgene Recognized as a “Specialized and Innovative” Enterprise Hillgene has recently been officially recognized as a “Specialized and Innovative” enterprise, a national designation granted by the Chinese government to companies that demonstrate outstanding capa... More+
• Industry Insight | Engineered “Bloodhound” Immune Cells May Offer a New Strategy for Targeting Solid Tumors March 2026 — Researchers at Stanford University School of Medicine have reported a new approach to engineering immune cells capable of detecting metabolic signals released by tumors, potentially impr... More+
• Instructions for Use of Host Cell RNA Residual Detection Kit for Escherichia coli（RT-qPCR）
• Industry Insight | The Race for NK Cell Therapy Is On: Who Will Cross the Finish Line First? If CAR-T therapy is the “star” of the immunotherapy field, then natural killer (NK) cell therapy is poised to become the next “top trend.” With its three core advantages—readiness for use, safety... More+
• Instructions for Use of Pichia Pastoris Hcp Elisa Assay Kit
• Industry Insight | Global CAR‑NK Cell Therapies Enter First-in-Human Trials, Accelerating Clinical Translation March 27, 2026 - The global immuno-oncology field is witnessing a significant milestone: several CAR‑NK (chimeric antigen receptor natural killer) cell therapy programs have now entered first-in-huma... More+